top stories

Spark Ther­a­peu­tics nabs new CMO from Genen­tech, fill­ing a ma­jor post-merg­er de­par­ture

10 hours ago
People

Phase III read­outs spell dis­as­ter for Genen­tech’s lead IBD drug

12 hours ago
R&D

Vi­da Ven­tures co-leads Dyne's $115M megaround for next-gen oli­go ther­a­pies aimed square­ly at mus­cles

9 hours ago
Venture

Rea­ta sug­gests Friedre­ich's atax­ia pro­gram could be de­layed, send­ing stock plung­ing

3 hours ago
Regulatory

Latest

Eli Lil­ly teams with Pieris on HER2+ tu­mors; Op­di­vo + Yer­voy best chemo in mesothe­lioma

9 hours ago
Protocols

In­novent and Eli Lil­ly chal­lenge Mer­ck­'s mega-block­buster Keytru­da in non-small cell lung can­cer field

9 hours ago
R&D

Anap­tys­Bio's etokimab pro­vides more dis­ap­point­ing re­sults, rais­ing ques­tions about com­pound's fu­ture

9 hours ago
R&D

The du­velis­ib hot pota­to is tossed to a new own­er as Ve­rastem looks to re­or­ga­nize around the pipeline

10 hours ago
Deals
R&D

Covid-19 roundup: Cure­Vac beefs up its uni­corn IPO dreams as bil­lion­aire own­er takes this Covid-19 mR­NA play­er on a ...

13 hours ago
Outsourcing
Pharma

UP­DAT­ED: Af­ter a 4-year so­journ, strug­gling mi­cro­bio­me pi­o­neer Seres claims a break­out PhI­II come­back. And shares ...

13 hours ago
R&D
see latest stream
People

Al­ny­lam pres­i­dent Bar­ry Greene leaves af­ter 17 years, hand­ing po­si­tion over to Yvonne Green­street as biotech looks ...

4 days ago

Cure­Vac nabs a top No­var­tis sci­en­tist for CSO slot as mR­NA vac­cines seize the spot­light

6 days ago

Rich Hey­man joins PMV Phar­ma, a p53 biotech, as it adds $70 mil­lion in Se­ries D

Last week
Startups

RA Cap­i­tal-backed Aerovate launch­es with $72.6M to treat PAH with a re­pur­posed can­cer med

4 days ago

Ver­sant funds TCR ther­a­py biotech T-knife's $78M+ Se­ries A to boost hu­man­ized T cell mice plat­form

4 days ago

Less than 3 months af­ter launch, the AveX­is crew’s Taysha rais­es $95M Se­ries B. Is an IPO next?

5 days ago
Deals

Bio­haven adds near­ly $1B in Nurtec deals with Roy­al­ty Phar­ma, Sixth Street

3 days ago

Ab­b­Vie aban­dons a pi­o­neer­ing CRISPR R&D al­liance with Ed­i­tas as Brent Saun­der­s' deal is cast out

4 days ago

Bio­gen hands De­nali $1B-plus in cash, $1B-plus in mile­stones to part­ner on late-stage Parkin­son’s drug

4 days ago
IPOs

Days af­ter seal­ing Sanofi pact, Kymera beats a path to the Nas­daq with $100M IPO pitch

Last week

AlloVir rides IPO boom on first mar­ket day, soars af­ter bag­ging $276 mil­lion

Last week

In­hi­brx takes a sec­ond shot at an IPO — this time bump­ing the goal to $100M-plus

Last week

Premium storiesSee all

So Covid-19 leader BioN­Tech has a can­cer vac­cine in de­vel­op­ment? Yes, and Re­gen­eron just jumped in for the PhII com­bo ...

Last week
Bioregnum
R&D

Af­ter Big Phar­ma aban­doned in­fec­tious dis­eases, 5 biotech con­trar­i­ans de­cid­ed to go all in. Then Covid-19 changed ...

2 weeks ago
People
Coronavirus

A wob­bly Bio­gen makes a sur­prise switch in the ex­ec­u­tive suite, trig­ger­ing a re­newed burst of M&A chat­ter

3 weeks ago
People

Gilead lines up a $1.55B biotech buy­out deal as CEO Dan O’Day in­vests in his lat­est can­cer block­buster dream

3 weeks ago
Deals

Don't missSee all

UP­DAT­ED: Bio­gen scores a pri­or­i­ty re­view for its Alzheimer's drug ad­u­canum­ab, mov­ing one gi­ant leap for­ward in its ...

3 days ago
R&D

Covid-19 roundup: Gates Foun­da­tion pours $150M in­to In­dia’s Serum In­sti­tute; Pfiz­er teams with Gilead on remde­sivir

3 days ago
Coronavirus

'Oc­to­ber is com­ing,' and every­one still wants to know if a Covid-19 vac­cine will be whisked through the FDA ahead of ...

4 days ago
Bioregnum
Coronavirus

Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remde­sivir; Hahn pleads with pub­lic to trust FDA's vac­cine ...

4 days ago
Coronavirus

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

4 months ago
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

7 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

9 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

10 months ago

Peer review See all

Aug
7

Alex­ion cre­ates new post for chief di­ver­si­ty of­fi­cer; Bar­ry Greene step­ping down at Al­ny­lam, Yvonne Green­street named ...

Jul
31

Tetraphase deal done, La Jol­la Phar­ma­ceu­ti­cal taps Lar­ry Ed­wards as CEO; Long­time Eli Lil­ly ex­ec Michael Over­dorf ...

Jul
24

Jeff Capel­lo out the door as Michael Mc­Don­nell takes over Bio­gen's CFO post; Ron Bruehlman named in­ter­im CFO at IQVIA

Jul
24

Turn­ing can­cer in­to a cur­able dis­ease: Im­munother­a­py ex­pert John Con­nol­ly picks up the reins as the new CSO of Sean ...

Jul
17

Tony Kings­ley takes over the reins at Schol­ar Rock; Idor­sia taps phar­ma vet Pa­tri­cia Torr for new US ops

R&D channel feed

3 days ago

When will it end? Big Phar­ma's top vac­cine ex­pert at OWS of­fers a speedy time­line for a Covid-19 vac­cine — ei­ther be­fore or right af­ter the elec­tion

Mon­cef Slaoui hasn’t start­ed mak­ing plans for his sum­mer va­ca­tion next year. But he of­fers high odds that all Amer­i­cans will be able to do that in the not too dis­tant fu­ture. In ...

READ MORE

Roche-backed Dicer­na push­es in­to the pack rac­ing to­ward the block­buster hep B goal line, armed with PhI da­ta

4 days ago

Per­cep­tive fields SPAC #3 as an­oth­er group of biotechs scoops up $364M in lat­est Nas­daq romp

3 days ago
latest in R&D

In sur­pris­ing set­back, com­bo of Roche’s Tecen­triq and chemo fails to help pa­tients with triple-neg­a­tive breast can­cer

3 days ago

Le­vo Ther­a­peu­tics miss­es pri­ma­ry end­point in PhI­II tri­al of Prad­er-Willi drug — the lat­est set­back in a dis­as­ter-prone field

4 days ago

Re­gen­eron adds more pos­i­tive PhI­II da­ta for its NGF pro­gram — but safe­ty is still a big con­cern

4 days ago

Pfiz­er's Lor­bre­na bests Xalko­ri in PhI­II read­out — is it a po­ten­tial suc­ces­sor?

4 days ago

FDA ap­proves GSK's BC­MA drug, mark­ing a rocky re­turn to can­cer for the British gi­ant

4 days ago
Regulatory
see latest stories

Pharma channel feed

3 days ago

UP­DAT­ED: FDA takes the lead on defin­ing es­sen­tial un­der Trump's 'Buy Amer­i­can' ex­ec­u­tive or­der — as phar­ma warns of sup­ply chain dis­rup­tion

Pres­i­dent Don­ald Trump has signed an ex­ec­u­tive or­der de­tail­ing how the fed­er­al gov­ern­ment should help on-shore drug man­u­fac­tur­ing — and the FDA will play a cen­tral role. The agency ...

READ MORE

Trump reach­es for his pen as long-await­ed ex­ec­u­tive or­der on drug man­u­fac­tur­ing on-shoring fi­nal­ly ar­rives — ...

4 days ago
Outsourcing

Sev­en plucky di­ag­nos­tics com­pa­nies win a $249M round of con­tracts af­ter sur­viv­ing NI­H's Covid-19 'Shark Tank' ...

Last week
Coronavirus
latest in Pharma

Bio­gen's last-ditch pitch for an in­junc­tion to pro­tect Tec­fidera is de­nied, paving way for My­lan gener­ic

Last week

Genen­tech slash­es near­ly 500 jobs in strate­gic shift to 'lo­cal health­care ecosys­tems.' Clin­i­cal spe­cial­ists make up the biggest group

Last week
R&D

Mod­er­na, Pfiz­er be­gin to give glimpse of Covid-19 vac­cine pric­ing — and prof­its

Last week
Coronavirus

Af­ter down year, 2020 brings new cash in­to Mass­a­chu­setts biotech

Last week
Venture

Trump looks to ham­mer down drug prices with 4 ex­ec­u­tive or­ders

3 weeks ago
see latest stories

Coronavirus channel feed

5 days ago

Mod­er­na CEO Stéphane Ban­cel out­lines a prospec­tive moth­er­lode of Covid-19 vac­cine rev­enue — will a back­lash fol­low?

Mod­er­na shows no sign of slow­ing down, or turn­ing char­i­ta­ble when it comes to pric­ing sup­plies of its Covid-19 vac­cine. One of the lead­ers in the Phase III race to get a ...

READ MORE

Covid-19 roundup: J&J and BAR­DA agree to $1 bil­lion for 100 mil­lion dos­es; Plas­ma re­duces mor­tal­i­ty by 50% — ...

5 days ago

FDA touts ad­vanced man­u­fac­tur­ing to ad­dress Covid-19 short­falls

5 days ago
Regulatory
latest in Coronavirus

No­vavax her­alds the lat­est pos­i­tive snap­shot of ear­ly-stage Covid-19 vac­cine — so why did its stock briefly crater?

6 days ago

Covid-19 roundup: FDA com­mis­sion­ers call for more ‘con­cert­ed ef­fort’ on con­va­les­cent plas­ma R&D; Re­gen­eron boosts case for an­ti­body cock­tail with new an­i­mal da­ta

6 days ago

OWS' Mon­cef Slaoui lam­basts ‘in­sult­ing’ me­dia cov­er­age: 'How are you help­ing in this pan­dem­ic?'

6 days ago

When will it end? Gold­man econ­o­mist gives late-stage vac­cines a good shot at tar­get­ing 'large shares' of the US by mid-2021 — but the down­side is daunt­ing

Last week
R&D

Covid-19 roundup: Eli Lil­ly retro­fits RVs for first-of-its-kind an­ti­body tri­al with NIH; Am­gen, Ab­b­Vie, Take­da team on a drug

Last week
see latest stories